Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Study Overview
=================
Brief Summary
-----------------
Glioblastoma (GBM) comprises about 16% of all malignancies of the nervous system and over 50% of all gliomas. Standard of care for newly-diagnosed GBM is a combination of surgical debulking followed by concurrent radiotherapy and chemotherapy with temozolomide. Efforts to improve second-line therapy in GBM have met with only marginal success and there is a large unmet medical need for new therapies. G-202 (mipsagargin) is an example of prodrug chemotherapy. It is activated by Prostate Specific Membrane Antigen (PSMA), which is expressed by some cancer cells and in the blood vessels of most solid tumors, including GBM, but not by normal cells or blood vessels in normal tissue. It is believed that activation of the prodrug G-202 will allow the drug to kill cancer cells. This study will evaluate the activity, safety and CNS exposure of G-202 in patients with recurrent or progressive GMB receiving G-202 by intravenous infusion on three consecutive days of a 28-day cycle. Funding Source - FDA OOPD

Official Title
-----------------
An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

Conditions
-----------------
Glioblastoma Multiforme

Intervention / Treatment
-----------------
* Drug: G-202


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent to participate in this study Histological or radiological confirmation of glioblastoma Recurrent or progressive GBM following at least one (1), but no more than two (2) prior regimens; one of the prior regimens must have included surgery and/or radiotherapy Age > 18 years Karnofsky Performance Status (KPS) ≥ 60% Life expectancy > 2 months Adequate hematologic, renal and hepatic function Adequate coagulation profile Not pregnant, nursing or planning to become pregnant; willing to use contraception Exclusion Criteria: Deteriorating neurological symptoms, or need for increasing doses of corticosteroids or new onset of seizures Surgical resection or major surgery within 4 weeks or stereotactic biopsy within 1 week of first G-202 treatment Toxicity from prior therapy (excluding alopecia) that has not resolved to ≤ Grade 1 unless otherwise specified Investigational or cytotoxic therapy within 28 days or nitrosoureas within 42 days of the first treatment with G-202 Currently requiring any type of full-dose anti-coagulation treatment, systemic administration of antibiotics or chronic administration of anti-viral agents. History or evidence of cardiac risk, including QTc interval on screening ECG >470 msec, left ventricular ejection fraction (LVEF) < 50%, clinically significant uncontrolled arrhythmias or arrhythmia requiring treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia, history of acute coronary syndromes within 6 months prior to the first dose of study therapy (including myocardial infarction and unstable angina, coronary artery bypass graft, angioplasty, or stenting) Uncontrolled cardiac or coronary artery disease Uncontrolled hypertension (mean systolic BP ≥ 160 mm Hg and/or mean diastolic BP ≥ 100 mm Hg on 3 determinations 5 minutes apart while on 2 anti-hypertensive agents) or hypertension requiring treatment with more than 2 anti-hypertensive agents Severe or uncontrolled medical disease, including uncontrolled diabetes, congestive heart failure, chronic renal disease or chronic pulmonary disease Severe GI bleeding within 12 weeks of treatment with G-202 Known history of HIV, hepatitis B or hepatitis C Documentation of keratosis follicularis (also known as Darier or Darier-White disease) Requirement for chronic use of strong inhibitors or inducers of cytochrome (CYP3A4) iso-enzymes Known hypersensitivity to any study drug component including thapsigargin derivatives, polysorbate 20, or propylene glycol Any other condition, including concurrent medical condition, social circumstance or drug dependency, which in the opinion of the investigator could compromise patient safety and/or compliance with study requirements Another primary malignancy that has not been in remission for at least 2 years; non-melanoma skin cancer, intraepithelial carcinoma of the cervix, or prostate cancer with a current PSA ≤ 0.1 ng/mL is allowed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: G-202 (Mipsagargin)<br>G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle | Drug: G-202<br>* G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6-month progression-free survival | Percentage of patients who received at least 2 cycles of G-202 and have not progressed, according to criteria of the Response Assessment in Neuro-Oncology Working Group (RANO), or died within 6 months of beginning treatment with G-202 | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety | Proportion of patients experiencing treatment-emergent adverse events | Every 2 weeks for approximately one year | 
| Objective tumor response rate, best overall response | Response rate assessed by RANO criteria | Every 8 weeks for approximately one year | 
| Duration of PFS | Duration of time from the first administration of G-202 until the first documented progression or date of death, assessed up to 12 months | Every 4 weeks for approximately one year | 
| Overall survival | Duration of time from the first administration of G-202 until the date of death, assessed up to 12 months | Every 4 weeks for approximately one year | 
| G-202 pharmacokinetics and pharmacodynamics | G-202 levels in CSF and serum; biomarkers in CSF, tumor and serum | Within 4 weeks of receiving G-202 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glioblastoma